Skip to main content
main-content

Melanoma

12-08-2019 | Oncology | News | Article

Individuals with autoimmune disease ‘good candidates’ for cancer immunotherapy

A French database analysis lends further support for the use immune checkpoint inhibitors for cancer in patients with pre-existing autoimmune disease.

31-07-2019 | Oncology | News | Article

Durable survival with nivolumab in patients with advanced RCC, NSCLC

Five-year data from the phase I CA209-003 trial indicate that the PD-1 inhibitor nivolumab is associated with long-term survival benefits among heavily pretreated patients with advanced renal cell carcinoma or non-small-cell lung cancer.

28-06-2019 | Oncology | News | Article

Checkpoint inhibitor rechallenge feasible after irAE-related discontinuation

Two studies point to the feasibility of resuming immune checkpoint inhibitors in patients who discontinue treatment due to immune-related adverse events.

07-05-2019 | Oncology | News | Article

Immunotherapy-related AEs reviewed, underlying mechanism postulated

Researchers have comprehensively analyzed the incidence of adverse events in trials of PD-1 and PD-L1 inhibitors, while another team has provided insight into the potential pathophysiologic process underlying these effects.

29-03-2019 | Oncology | News | Article

Flu vaccine not contraindicated for checkpoint inhibitor-treated cancer patients

A US chart review has found no increase in the incidence of severe immune-related adverse events among advanced cancer patients who receive an influenza vaccination during the 2 months before or after initiating immune checkpoint inhibitor therapy.

30-10-2018 | Oncology | News | Article

Continued benefits of immunotherapy shown in advanced melanoma

An updated analysis of the CheckMate 067 trial shows continued survival benefits at 4 years with nivolumab plus ipilimumab or nivolumab monotherapy versus ipilimumab alone in patients with previously untreated advanced melanoma.

Image Credits